This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Retinal Detachment  • Vitreoretinal Surgery  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Liu Yang, MD, PhD; Joon-Hyun Kim, MD, PhD; Kyle D. Kovacs, BA; Jorge G. Arroyo, MD, MPH; Dong F. Chen, MD, PhD

Arch Ophthalmol. 2009;127(11):1475-1480.

Objective  To determine whether systemic minocycline can protect photoreceptors in experimental retinal detachment (RD).

Methods  Retinal detachment was induced in mice by subretinal injection of sodium hyaluronate, 1.4%. In 1 experiment, mice received daily injections of minocycline (group 1) or saline (group 2). In a second experiment, mice were treated with minocycline or saline beginning 24 hours prior, immediately after, or 24 hours after experimental RD. In both experiments, photoreceptor cell survival and apoptosis were assessed by immunohistochemistry with primary antibodies against photoreceptor cell markers, rod rhodopsin, and cone opsin, and by terminal deoxynucleotidyl transferase-mediated dUTP-biotin end labeling.

Results  Photoreceptor cell apoptosis was detected at day 1 after experimental RD, with apoptotic cells peaking in number at day 3 and dropping by day 7. Treatment with minocycline significantly reduced the number of apoptotic photoreceptor cells associated with RD when given 24 hours before or even 24 hours after RD.

Conclusions  Our data suggest that minocycline may be useful in the treatment of photoreceptor degeneration associated with RD, even when given up to 24 hours after RD.

Clinical Relevance  Use of minocycline in patients with macula-off RD may prevent photoreceptor apoptosis and glial cell proliferation, improving final visual outcomes.

Author Affiliations: Department of Ophthalmology, Peking University First Hospital, Beijing, China (Dr Yang); Department of Ophthalmology, Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts (Drs Yang, Kim, and Chen); and Division of Ophthalmology, Beth Israel Deaconess Medical Center, Department of Ophthalmology, Boston (Drs Kim and Arroyo and Mr Kovacs).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?